Strains of Aspergillus fumigatus, Aspergillus flavus, and Aspergillus niger were tested for in vitro susceptibility to amphotericin B alone and in combination with fixed concentrations of tetracycline, doxycycline, or minocycline, using buffered minimal essential medium in microtiter plates. Enhanced inhibitory activity was seen, especially with combinations of amphotericin B and minocycline. Synergistic activity between amphotericin B and minocycline was observed in each of five isolates of each species when tested in a checkerboard dilution scheme. Time-kill curves demonstrated killing an A. fumigatus isolated at concentrations of amphotericin B that were four-or eightfold lower in the presence of 5 or 15 ,ug of minocycline per ml than with amphotericin B alone. Of the tetracycline analogs tested, minocycline has the greatest activity against A. fumigatus, A. flavus, and A. niger conidia when potentiated by amphotericin B.
The addition of flucytosine or rifampin to amphotericin B has previously been shown (10, 13) to enhance the in vitro activity of amphotericin B against Aspergillus fumigatus, Aspergillus flavus, and Aspergillus niger, despite the apparent lack of useful activity of either flucytosine or rifampin alone against these organisms. The efficacy of these combinations was also shown in an experimental animal model of aspergillus infection (2) . Amphotericin B binds to sterols in the fungal cell membrane and increases permeability (12) , allowing entry and subsequent interference with RNA synthesis by flucytosine or rifampin, as shown by Medoff and co-workers against yeast cells (17) .
Tetracycline inhibits yeast protein synthesis in cell extracts but not in whole cells due to its inability to penetrate the cell (4) . In the presence of a subinhibitory concentration of amphotericin B, tetracycline reduces colony counts of Saccharomyces cerevisiae by specifically inhibiting protein synthesis (14) . Amphotericin B has also previously been shown to potentiate the in vitro activity of tetracycline analogs doxycycline and minocycline against Candida albicans (1, 15) .
In this study, we evaluated strains of A. fumigatus, A.
flavus, and A. niger for in vitro susceptibility to combinations of amphotericin B with tetracycline, doxycycline, or minocycline. In addition, the synergistic and fungicidal potentials of these drug combinations were determined. Media. Microtiter plates were prepared with Eagle minimal essential medium (GIBCO Laboratories, Grand Island, N.Y.) buffered with 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethane-sulfonic acid) with a final pH of 6.5. Our previous studies (10) have shown this medium to produce comparable, although slightly higher, MICs against Aspergillus spp. than buffered yeast nitrogen base in testing with a variety of antifungal agents and combinations.
Inoculation. Strains of A. fumigatus (12), A.flavus (5), and A. niger (5) were grown on potato glucose agar at 37°C for 3 to 7 days. Conidia were harvested by lightly swabbing the surface of the plate and suspended in saline; the resulting suspensions contained virtually all conidia by microscopic examination. The suspensions were then shaken in saline with glass beads, washed twice, and suspended in saline; final suspensions were adjusted to 95% transmittance at 530 nm (-5 x 105 to 1 x 106 spores per ml by plate count).
Microtiter plates were inoculated in duplicate with each suspension by using a disposable inoculator that delivered 0.01 ml into each well. Plates were incubated at 37°C for 24 h.
Susceptibility determination. Microtiter plates were examined for fungal growth at 24 h. The MIC was defined as the first well showing no visible growth.
Killing curves. Suspensions of a typical A. fumigatus isolate were inoculated in duplicate into microtiter plates as described above. At 0 and 4 h, entire wells (100 ,ul) were emptied into 10 ml of saline and vigorously shaken, and 100-,ul samples were plated onto blood agar plates for (Fig. 3) . doxycycline at a concentration of 15 ,ug/ml (data not shown), a twofold reduction in amphotericin B concentration required for cidal activity was seen. There was generally good agreement between replicate plate counts and 10-fold dilutions.
The checkerboard studies demonstrated synergism between amphotericin B and minocycline against all five isolates of A. fumigatus, A. flavus, and A. niger (Table 1) . The lowest Y.FICs were observed in the rows containing 7.8 or 15.6 ,ug of minocycline per ml.
DISCUSSION
In a study similar to ours with C. albicans, Lew et al. (15) found the greatest synergistic inhibitory activity between amphotericin B and minocycline. Doxycycline was intermediate, and tetracycline was potentiated least by amphotericin B. We found the same order of activity against Aspergillus spp. Interestingly, the lipophilic nature of the drugs, as measured by their apparent partition coefficients, is greatest for minocycline; doxycycline is intermediate, and tetracycline is least lipophilic (3). In addition, minocycline is unique in that it is most lipophilic at a near-neutral pH, which may presence of a 5-,Ug/ml account for its relatively greater penetration into brain, thyroid, and fat tissues. Amphotericin B is thought to interact with sterols in fungal cell membranes, forming complexes that allow enhanced cell membrane permeability (16) . The lipophilic nature of minocycline may allow entry into cells that are relatively less permeable, perhaps by interacting with the free fatty acids that are found in fungal cell membranes (8) .
There has been concern that tetracycline and analogs may have a detrimental effect on the phagocytic and chemotactic activities of leukocytes (5) . Recent work indicates that these in vitro effects are mediated by the divalent cation-chelating activity of the drugs (6) and are highly dependent on cation concentrations. Hence, the in vivo significance of these observations is not known. The small amount of in vivo data addressing amphotericin B-tetracycline combinations against experimental infections with organisms other than Aspergillus spp. suggests additive activity (11, 18) or no difference (7) when compared with amphotericin B alone.
Aspergillus infections present formidable problems in therapy due to the toxicity and marginal efficacy of amphotericin B administration. The addition of flucytosine to amphotericin B adds the risk of bone marrow suppression in patients who are often already neutropenic. Thus, there is a need for less toxic agents which have activity against Aspergillus spp. when potentiated by amphotericin B. Based on our study and previous work with other fungi, evaluation of in vivo 
